Lumos Pharma Inc

Lumos Pharma — Technical Presentation (April 2021)

55 slides from Lumos Pharma's technical presentation, Apr 29, 2021

  1. Slide 1: Pediatric Growth Hormone Deficiency and LUM-201 KOL Event

    1 Pediatric Growth Hormone Deficiency and LUM-201 KOL Event April 27, 2021

  2. Slide 2: Forward Looking Statements

    2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, within the meaning of T

  3. Slide 3: Agenda

    3 Agenda Lumos Pharma Corporate Overview – Rick Hawkins, CEO The Future of Therapy for Growth Hormone Deficiency – Bradley S. Miller, MD, PhD Oral Growth Hormone Secretagogue, LUM-201, Pulsatile Effect – Fernando Cassorla, MD Questions & Answers

  4. Slide 4: Investment Highlights

    4 Investment Highlights * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Late-stage Rare Disease Asset Large Markets Experienced Management Solid Cash Position Pipeline Expansion • Novel oral therapeutic asset, LUM-201 • Phase 2b in Pediatric

  5. Slide 5: Management – Significant Clinical Development and Commercial Experience

    5 Management – Significant Clinical Development and Commercial Experience Richard Hawkins Chairman, CEO & President Developed Growth Hormone (GH) Receptor Antagonist for Acromegaly at Sensus (sold to Pfizer). Built one of the first contract recombinant protein manufacturing facilities (Covance Biote

  6. Slide 6: Key Opinion Leaders

    6 Key Opinion Leaders Dr. Bradley S. Miller1 is currently Professor, Department of Pediatrics and Faculty Member, Division Director, Division of Pediatric Endocrinology, at the University of Minnesota Medical School. He is a practicing pediatric endocrinologist and published research investigator wi

  7. Slide 7: The Future of Therapy for Growth Hormone Deficiency

    The Future of Therapy for Growth Hormone Deficiency April 27, 2021 Bradley S. Miller, MD, PhD Professor and Director Division of Endocrinology Department of Pediatrics University of Minnesota Masonic Children’s Hospital ity of Minnesota hile pital

  8. Slide 8: Disclosure

    Disclosure ¢ Dr. Miller is a consultant for Abbvie, Ascendis, BioMarin, Novo Nordisk, Orchard, Pfizer, Sandoz, Sanofi Genzyme, Tolmar and Vertice and has received research support from Alexion, Abbvie, Amgen, Ascendis, Lumos Pharma, Novo Nordisk, Opko, Pfizer, Sandoz, and Tolmar. * [will be discussi

  9. Slide 9: Hypothalamus GH-IGF Axis (Somatomedin Hypothesis)

    Hypothalamus GH-IGF Axis (Somatomedin Hypothesis) Kupffer cells hepatic endothel Slide courtesy of P. Cohen

  10. Slide 10: Growth Hormone Deficiency

    10 Growth Hormone Deficiency * Growth Failure * Decreased Pituitary Growth Hormone Production ¢ Low GH causes Low IGF-1 Normal Limited Very Limited/No GH Release GH Release GH Release Atle) rare) ann Spectrum of Pediatric Growth Hormone Release

  11. Slide 11: Growth Hormone Deficiency

    " Growth Hormone Deficiency ¢ Incidence: 1 in 3500 * Etiology — Idiopathic (majority) — Organic (congenital, acquired) Normal Limited Very Limited/No GH Release GH Release GH Release WW rrr Spectrum of Pediatric Growth Hormone Release Lindsay R, et al, J Pediatr.125:29, 1994, ity of Minnesota hildre

  12. Slide 12: Growth Hormone Deficiency Patients Have a Range of Secretion Insufficiency

    Growth Hormone Deficiency Patients Have a Range of Secretion Insufficiency Awide range of severity in GHD’ - Variability in responses to GH therapy - More severely deficient patients respond better than partially deficient’ + Several prediction models attempt to explain variability and optimize GH t

  13. Slide 13: Daily Growth Hormone FDA Approvals

    13 Uni Masonic Daily Growth Hormone FDA Approval: Children: Growth Hormone Deficiency Turner Syndrome Small for Gestational Age Chronic Renal Insufficiency Prader Willi Syndrome Idiopathic Short Stature SHOX Deficiency Noonan Syndrome Adults: Growth Hormone Deficiency Aids Wasting Short Bowel Syndro

  14. Slide 14: Daily Growth Hormone

    4 Daily Growth Hormone Pros: Overall Safe >500,000 patient years safety data (long-term data still needed) Adult Height near mid-parental target height in children with GHD Established Short-Term Efficacy in Adults Cons: Daily Injection Cost

  15. Slide 15: How Long does GH last?

    How Long does GH last? * Clearance from circulation — Glomerular filtration/renal metabolism — Receptor-mediated uptake — Extracellular proteases? * Half life after IV injection: 14-19 minutes * Half life after endogenous pulse: 25 minutes * Half life after SQ injection: 2.1 hours 1000 100 Serum GH

  16. Slide 16: How Long does GH last?

    How Long does GH last? 24-hour serum GH profiles seers GHD mean —} Normal — 0.043 mg/kg S.C. * Clearance from circulation 10 — Glomerular filtration/renal metabolism 8 — Receptor-mediated uptake +— Daily injections toa) — Extracellular proteases? NGH (ng/m1) * Half life after IV injection: 14-19 min

  17. Slide 17: Challenges with Daily GH Therapy

    7 Challenges with Daily GH Therapy * Potential for an Hippocrates was the first to note Ghat Improvement help — Adherence — Injection some patients did not take choir mediones as prescribed, and later complained (hae their treatment did not “Drugs don't work in || united States Ee Patients, n Data s

  18. Slide 18: 18

    18

  19. Slide 19: Administration burden of daily GH therapy

    19 100 Responders, % v b @2 @ 6s ¢ 8 & ° Administration burden of daily GH thera 54.1 32.8 35.9 Cause bruising Are painful Injection experience Patients (n=61) mCaregivers (n=237) Kremidas D, et al. J Ped Nurs 2013;28:55-63 37.7 26.8 Cause stinging

  20. Slide 20: Long-Acting GH Therapies

    Long-Acting GH Therapies Will LAGH be Superior to Daily rhGH? Daily rhGH Inconvenient, painful and distressing daily injections ~ Lack of adherence > Reduced efficacy and increased healthcare costs @ LAGH may increase overall treatment outcomes via improved adherence, superior serum IGF-1 levels and

  21. Slide 21: Overview of LAGH Preparations in Development

    at Overview of LAGH Preparations in Development [__PGHD _] Jintrolong® (Genser) [—AGHD Marketed ISS, SGA, TS ‘The LAGH with the maximum long-term safety and efficacy evidence at present Marketed P/AGHD: pediatric/adult growth hormone deficiency ISS: idiopathic short stature SGA: small for gestationa

  22. Slide 22: GH Secretagogue

    22 GH Secretagogue * Molecules that stimulate release of Growth Hormone Releasing Hormone (GHRH), GH or both.

  23. Slide 23: The Spectrum of GH Deficiency and the Importance of Pulsatility

    23 The Spectrum of GH Deficiency and the Importance of Pulsatility Growth Hormone (GH) is naturally released in the body in a pulsatile fashion For children who have the ability to secrete a small amount of GH on their own, one potential approach to PGHD therapy is to increase the patients’ own “wav

  24. Slide 24: How does LUM-201 work?

    24 How does LUM-201 work? And what is a secretagogue? It works on receptors Hypothalamus cs 2 i i sst 2 GHRH |S * in the brain Pl a E Pituitary |[S- to help you stimulate your own pulsatile production of natural growth hormone Asecretagogue is a substance that promotes secretion. LUM-201 is a secret

  25. Slide 25: What is LUM-201 and how is it different from injectable rhGH?

    25 What is LUM-201 and how is it different from injectable rhGH? * Itis not an injection. * Itis not rhGH in a pill form. Moving from needles to oral therapy It is a small molecule that stimulates the body's own pulsatile production of growth hormone It is an oral medication 81mg baby aspirin Taken

  26. Slide 26: PEMs Enrich Trials for Patients with Functional But Reduced GH Secretion

    26 PEMss Enrich Trials for Patients with Functional But Reduced GH Secretion Moderate (PEM +): Included in Clinical Trials Severe (PEM -): Excluded from Clinical Trials Hypothala thal — - iP eat e< 1 Pituitary e Functional but reduced HP-GH axis Non-functional HP-GH axis © Able to secrete some, but

  27. Slide 27: PEM Segmentation Aligns With Patients' Baseline Characteristics

    ar PEM Segmentation Aligns With Patients’ Baseline Characteristics GeNeSIS'* 12,315 GHD 514 isolated GHD Chronological age (y) 6.80 7.10 Baseline | Height SDS -3.01 -2.58 Height veloci 9.62 8.29 cy velocity (cm/y) Height SDS -2.16 -2.00 Data from large database: Corroborate PGHD population segmentat

  28. Slide 28: Study Post-Hoc Analysis: PEM-Positive Patients Responsive to LUM-201

    Study 020 Post-Hoc Analysis: PEM- Positive Patients Responsive to LUM-201 PEM = Predictive Enrichment Marker + Naive PGHD, Merck Study 0201 , ; = — N=68; three arms » All Subjects PEM-Negative PEM-Positive — Placebo patients switched to thGH at 6 months - Annualized growth shown for each arm + PEM-p

  29. Slide 29: PK/PD: Evidence of a PK and PD Dose Response in Healthy Volunteers

    29 PK/PD: Evidence of a PK and PD Dose Response in Healthy Volunteers Pharmacokinetics Pharmacodynamics Dose response to 5.6 mg/kg PGHD PD plateau possible > 2.8 mg/kg PGHD dose equivalent* dose equivalent* © 200 mg adult (66 mg/kg PGHO) 1000 80 A 100mg adit (28 moka PGHO} -& SOmg adit (1.4 mg/kg PG

  30. Slide 30: LUM-201 Effects Are Durable In Healthy Elderly

    LUM-201 Effects Are Durable In Healthy Elderly A 8 ~@ Placebo (n = 22) ~@ Placebo (n = 22) 26 I MK-677 (n= 43) 100 IB MK-677 (n = 43) 160-} Low normal for young . 7 140-4 adults (116-358 pg/L) 1 24-h Mean GH Level (95% CD, pg/L Serum IGF Level (95% Cl), yg/L 20. Ce ar 4o-| bow normal for older adult

  31. Slide 31: OraGrowtH210 Trial: Phase 2b Trial in PGHD

    OraGrowtH210 Trial: Phase 2b Trial in PGHD Srcutl <a OraCrowtii210 Total Study Duration — 6 months N=20 LUM-201: 0.8 mg/kg/day Goals: * Prospectively confirm utility of PEM strategy + n=80 + PEM(+) PGHD patients + Inclusion: stim GH > 5ng/ml and baseline IGF-1 > 30ng/mi of PEM a 6 A + Determine opti

  32. Slide 32: Summary

    32 Summary LUM-201 stimulates pulsatile secretion of endogenous GH and has the potential to improve growth in the majority of children with GHD and non-GHD growth disorders. Use of the Predictive Enrichment Marker should identify those children that are able to respond to LUM-201. Due to the presenc

  33. Slide 33: Pediatric Endocrinologist

    Pediatric Endocrinologist Professor of Pediatrics Director of Growth Programs Director, Division of Pediatric Endocrinology University of Minnesota Masonic Children’s Hospital 8952D, East Bldg MB671 2450 Riverside Avenue Minneapolis, MN 55454 612-624-5409 BEM mille685@umn.edu

  34. Slide 34: Effects of the oral GH secretagogue LUM-201 over pulsatile GH secretion and linear growth

    Effects of the oral growth hormone (GH) secretagogue LUM-201 (Ibutamoren) over pulsatile GH secretion and linear growth in children with moderate GH deficiency Fernando Cassorla MD Chief of Pediatric Endocrinology Institute of Maternal and Child Research University of Chile, Santiago, Chile

  35. Slide 35: Disclosure

    Disclosure Fernando Cassorla M.D. Dr. Cassorla is an investigator for clinical studies with LUM-201 at the University of Chile and has previously acted as a consultant for Debiopharm, Pfizer, Merck and Sandoz. LUM-201 is an investigational compound and is not approved for use by the FDA or any other

  36. Slide 36: Effects of oral administration of ibutamoren mesylate on the GH-IGF-I axis

    Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children Ethel Codner, MD, Fernando Cassorla, MD, Anatoly N. Tiulpakov, MD, PhD, M. Veronica Mericq, MD, Alejandra Avil

  37. Slide 37: Change in peak GH response after oral Ibutamoren administration

    Change in peak GH response after oral Ibutamoren administration for 8 days in GH deficient children 604 +— Baseline IGF-1 < 50 ng/mL. ——> <— Baseline IGF-1 > 50 ng/mL. ——> sot @ Peak GH response to stim-0.8mg/kg ibutamoren on day 15 40+ © Baseline GH 304 Peak GH (ug/L) 204 wl Seo Ses ot 3 id { ve T

  38. Slide 38: LUM-201 (Ibutamoren) Mechanism of Action

    LUM-201 (Ibutamoren) Mechanism of Action Hypothal: "armas |S — [uo SST + GHRH — * Oral LUM-201 is a growth hormone (GH) secretagogue ®LYSHO ¢ Acts as an agonist of GH Secretagogue Receptor (GHSR1a) to stimulate GH release? ¢ LUM-201 has been observed to increase the amplitude of endogenous, pulsatil

  39. Slide 39: Questions

    Questions 1. Does LUM-201 augment endogenous GH pulses in patients with moderate GH deficiency? 2. Will increased GH pulses improve height velocity? 3. Can these responses be predicted from baseline testing?

  40. Slide 40: Predictive Enrichment Markers for Patients with Functional, But Reduced GH Secretion

    Predictive Enrichment Markers for Patients with Functional, But Reduced GH Secretion MODERATE GH deficiency: Included in Trials SEVERE GH deficiency: Excluded from Trials Hypothalamus 2 lamus_ 2 = Es SST 25 GHRH |S * (an et z SSS 5 - 2 Functional but reduced pituitary axis o Able to secrete some, bu

  41. Slide 41: GH Pulsatility in Naive Prepubertal Patients with GH Deficiency

    GH Pulsatility in Naive Prepubertal Patients with GH Deficiency Screening Baseline 6 months Standard GH Height aici stimulation tests IGF-1 IGF-1 Peak GH to single Q20m 24h GH Q20m 24h GH LUM-201 dose* Screening/Baseline Height Standard GH Peak GH to single aes velocity stimulation tests LUM-201 dos

  42. Slide 42: Axis Responsive to LUM-201: Patient A

    Axis Responsive to LUM-201: Patient A Q20m 24h GH Patient A ~* Baseline 30 6 months Baseline LUM-201 24 0.8 mg/kg/d = oo IGF-1 (ng/ml) 182 Mean (ng/ml) 3.4 AUC (ng*hr/ml) 75.5 Height velocity (cm/yr) 3.7 = iy Serum Growth Hormone (ng/ml) oO 0 01234 5 6 7 8 9 101112131415 1617 18 19 20 21 22 2324 Sam

  43. Slide 43: Axis Responsive to LUM-201: Patient A

    Axis Responsive to LUM-201: Patient A IGF-1 (ng/ml) Q20m Mean (ng/ml) 24hGH | AUC (ng*hr/ml) Height velocity (cm/yr) 10 Baseline 182 3.4 75.5 Co 2 6 months LUM-201 | 0.8 mg/kg/d Serum Growth Hormone (ng/ml) o So a = ny Q20m 24h GH Patient A ~* Baseline -® 6months 0123 4 5 6 7 8 9 101112131415 1617 1

  44. Slide 44: Axis Responsive to LUM-201: Patient B

    11 Axis Responsive to LUM-201: Patient B 6 months Baseline LUM-201 0.8 mg/kg/d IGF-1 (ng/ml) 53 Mean (ng/ml) 1.0 AUC (ng*hr/ml) 17.6 Height velocity (cm/yr) 3.5 Serum Growth Hormone (ng/ml) “0.42345 67 8 9 101112131415 1617 18 192021 22.2324 Sampling Time (hr) Merck 020 trial

  45. Slide 45: Axis Responsive to LUM-201: Patient B

    Axis Responsive to LUM-201: Patient B Q20m 24h GH Patient B ~* Baseline -® 6months 3.0 | 6months fi Baseline | LUM-201 [iE | 0.8 mg/kg/d #4 s 5 2 IGF-4(ngml) 53 | 72 E Z14 Q20m Mean (ng/ml) 1.0 5 ; 24nhGH | AUC (ngthriml) 17.6 8 , 2 0.! Height velocity (cm/yr) 3.5 89 a 0123.45 67 8B 9 10111213 14151

  46. Slide 46: Axis Not Responsive to LUM-201: Patient C

    Axis Not Responsive to LUM-201: Patient C Q20m 24h GH Patient C ~* Baseline 1.2 6months [iS Baseline LUM-201 1.0 0.8 mg/kg/d IGF-1 (ng/ml) 17 Mean (ng/ml) 0.5 AUC (ng*hr/ml) 4.9 Height velocity (cm/yr) 1.1 2 a Serum Growth Hormone ( o > 0123 45 6 7 8 9 101112131415 1617 18 19 20 21 2223 24 Sampling

  47. Slide 47: Axis Not Responsive to LUM-201: Patient C

    Axis Not Responsive to LUM-201: Patient C Q20m 24h GH Patient C ~* Baseline -* 6months 1.2 6 months Baseline LUM-201 1.0 0.8 mg/kg/d IGF-1 (ng/ml) 17 Mean (ng/ml) 0.5 AUC (ng*hr/ml) 4.9 Height velocity (cm/yr) ‘od Ss b Serum Growth Hormone (ng/ml) ° ° iy a 0123.45 67 8 9 10111213 14151617 18 19 2021

  48. Slide 48: Status of Hypothalamic Pituitary GH Axis

    15 Status of Hypothalamic Pituitary GH Axis Patients A& B Patient C Axis Responsive Axis Not Responsive Q Q Hypothalamus i: _aa Hypothalamus Eee LUM-201 SST 5 GHRH > SST 4 GHRH > Loy Loy 2 2 Pituitary |e3 Pituitary |e2 : x GH v IGF-1 SST = somatostatin ne GHRH = growth hormone-releasing hormone ‘§ I

  49. Slide 49: LUM-201 can stimulate pituitary GH secretion and improve height velocity

    LUM-201 can stimulate pituitary GH secretion and improve height velocity in children with moderate GH deficiency ¢ Patients A&B - Baseline IGF-1 > 30 ng/mL and peak GH to single LUM-201 dose 2 5 ng/mL* - 24-hour GH is augmented less than two-fold - Height velocity is improved e Patient C - Baseline

  50. Slide 50: Further studies of LUM-201 in pediatric patients are required

    17 Further studies of LUM-201 in pediatric patients with moderate growth hormone deficiency are required in order to confirm that: - LUM-201 increases endogenous GH pulsatility - Augmented GH pulsatility improves height velocity - Augmentation of GH pulsatility and improvement of height velocity by

  51. Slide 51: Clinical study of LUM-201 in naive pediatric patients at the University of Chile

    18 Clinical study of LUM-201 in naive pediatric patients with moderate GH deficiency at the University of Chile 24 prepubertal patients between the ages of 4 to 8 years (girls) and 10 years (boys) with short stature caused by moderate GH deficiency, and naive to GH treatment, will be assigned random

  52. Slide 52: LUM-201 in naive prepubertal patients with GH deficiency

    LUM-201 in naive prepubertal patients with GH deficiency ___LUM-201 1.6 mg/kg/day N=12 Screening Baseline 6 months Standard GH Height Height stimulation tests IGF-1 IGF-1 Peak GH to single Q10m 12h GH Q10m 12h GH LUM-201 dose** Screening Baseline 6 months Standard GH Height Height stimulation tests

  53. Slide 53: Expected results

    20 Expected results - We will document any increase in the height velocity of these prepubertal patients with moderate GH deficiency treated with LUM-201, which may be dependent on the dose employed. - The improved height velocity during LUM-201 administration will be correlated with an increase in

  54. Slide 54: Institute of Maternal and Child Research

    Institute of Maternal and Child Research ediatric Team, University of Chile cS 25g ee wae ‘ Pee , a te" Sas gS

  55. Slide 55: Q & A

    55 Q & A

Lumos Pharma — Technical Presentation (April 2021) on 6ix